Mandatory folic acid fortification of grains such as wheat flour has been introduced in several countries to reduce the incidence of neural tube defects. There are concerns, however, that folic acid could mask the hematologic signs of vitamin B-12 deficiency and lead to other adverse health outcomes in the population. Calcium L-5-methyltetrahydrofolic acid (L-5-MTHF), a synthetic form of reduced folate, should not mask vitamin B-12 deficiency and may be safer than folic acid.
Introduction
Mandatory folic acid fortification of grains has been introduced in several countries during the last 20 y to reduce the incidence of neural tube defects (NTDs) such as spina bifida (1) . In North America, enriched wheat flour is the predominant grain fortified with folic acid and thus bread is a major source of folic acid. Although folic acid fortification has reduced the incidence of NTDs (2, 3) , concerns exist about some undesirable health effects of folic acid intake on the population (4) . These include the potential masking of the hematologic signs of vitamin B-12 deficiency (5), increased colon cancer risk (6) , and cognitive impairment in the elderly, especially when high folic acid intakes are combined with suboptimal vitamin B-12 status (7) .
Folic acid is a synthetic, oxidized form of folate with good stability and bioavailability compared with naturally occurring folates; therefore, it is often used in dietary supplements or added as a fortificant in food. Calcium L-5-methyltetrahydrofolic acid (L-5-MTHF), a supplemental form of reduced folate, is now available. L-5-MTHF more closely resembles the biologically active form of natural folate and may be safer than folic acid (8, 9) . Most notable is that unlike folic acid, L-5-MTHF is unable to mask a vitamin B-12 deficiency (8, 9) . Folic acid may correct the megaloblastic anemia caused by vitamin B-12 deficiency, allowing the neurologic problems associated with vitamin B-12 deficiency to progress unchecked. In supplement form, L-5-MTHF has been shown to have bioavailability equivalent to or greater than folic acid based on its ability to increase blood folate concentrations in both acute and chronic studies in a variety of populations (10) (11) (12) (13) (14) (15) . However, L-5-MTHF is not very stable in foods such as bread products that are made with enriched flour. We previously characterized the degradation kinetics of L-5-MTHF when exposed to different temperatures and levels of acidity, thereby showing that the antioxidant sodium ascorbate in close contact with reduced folate is effective at ensuring stability (16) . Furthermore, we recently reported that microencapsulation of L-5-MTHF with sodium ascorbate using modified starch as the coating material is an effective means of preventing L-5-MTHF loss during bread making and storage (17) . The bioavailability in humans of microencapsulated L-5-MTHF added to bread is currently not known. In this paper, we report the results of a randomized, placebo-controlled trial designed to assess the efficacy of wheat rolls fortified with microencapsulated L-5-MTHF (452 mg) or equimolar folic acid (400 mg) compared with wheat rolls containing no added folate (placebo) at increasing blood folate concentrations during 16 wk.
Methods
Participants. Participants were recruited from Vancouver, Canada, through advertisement and word-of-mouth. Participants between 18 and 45 y and not taking a supplement containing folic acid were invited to take part in the study. Participants were not eligible if they had medical conditions such as diabetes, asthma, cancer, cardiovascular disease, high blood pressure, celiac disease, and psychiatric illness or were taking medications known to interfere with folate metabolism. Participants who had a known B-12 deficiency, wheat or cow milk allergy, or were lactose intolerant were also excluded. Participants who consumed >3 alcoholic drinks/d on average were not eligible. Women who were pregnant during the previous year, planning a pregnancy, might become pregnant during the study, or had a known previous NTD-affected pregnancy were not eligible to participate. The University of British Columbia Clinical Research Ethics Board approved the study and written informed consent was obtained from all participants.
Study design. A 16-wk, double-blind, randomized, placebo-controlled trial was conducted between May and September 2012. At baseline, participants attended a morning clinic following an overnight fast where blood was collected by venipuncture. Participants completed a health and demographic questionnaire that included questions on age, ethnicity, income, and education. Heights and weights were measured using standard methods. Forty-five participants were randomly assigned (n = 15/group) to receive a daily wheat roll formulated to contain L-5-MTHF, folic acid, or no folate (placebo). Participants were given 7 wheat rolls each week and were asked to consume 1 roll/d at their convenience. Participants were asked to keep the wheat rolls refrigerated and were given a diary to record wheat roll consumption. The number of wheat rolls not consumed and the diary review were used to assess compliance. Participants returned to the clinic at wk 8 and 16 to provide a fasting blood sample.
Microencapsulated L-5-MTHF. L-5-MTHF (calcium salt, Metafolin; Merck Eprova) was microencapsulated with a modified starch (HI CAP 100, National Starch) and sodium ascorbate as a stabilizer in a ratio of 0.1:91:9 (L-5-MTHF:starch:sodium ascorbate) (16, 17) . The recovery of L-5-MTHF after the spray-drying encapsulation process was assessed to be >96%. We previously showed greatly improved stability of L-5-MTHF in wheat rolls when it is microencapsulated (17) .
Organic, unbleached, folate-free, all-purpose flour was purchased from Whole Foods Market. This flour was fortified with folate to produce wheat rolls that contained either 452 mg L-5-MTHF/roll or 400 mg folic acid/roll. We chose this amount of folate, as the US Institute of Medicine has recommended that, in addition to consuming naturally occurring folates from a varied diet, women capable of becoming pregnant consume 400 mg/d of folic acid from fortified foods and/or supplements (18) . The fortified flour mix was routinely sampled to monitor the folate level and to ensure even distribution in the baked rolls as well as stability during storage. Wheat rolls (36 g each) were prepared each week in the department pilot plant food laboratory. Rolls were baked at 185°C for 25 min and packaged in air-tight bags. The folic acid and L-5-MTHF amounts were monitored in freshly baked wheat rolls as well as at d 3 and 7 post-baking (stored at 4°C).
Laboratory methods. L-5-MTHF and folic acid were extracted from the fortified flour and the baked wheat rolls using 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid/2-(cyclohexylamino)ethanesulfonic acid buffer (0.5 mol/L, pH 7.85) as previously described (19) . L-5-MTHF was detected using a fluorescent detector (excitation at 290 nm and emission at 365 nm). Folic acid was determined using the same gradient with UV detection at a wavelength of 290 nm. The concentrations of L-5-MTHF and folic acid were determined from external standards.
Blood samples for plasma and erythrocyte folate determination were collected in tubes containing EDTA and immediately placed on ice. A portion of whole blood was removed and hematocrit was measured in freshly collected blood with the use of a hematology analyzer. The remaining whole blood was centrifuged to obtain plasma. Plasma and whole blood were stored at 280°C until analyzed. Plasma folate and whole blood folate concentrations were determined using the microtiter technique described by OÕBroin and Kelleher (20) with chloramphenicolresistant Lactobacillus casei as the test microorganism. Erythrocyte folate was calculated from whole blood folate by subtracting plasma folate and correcting for hematocrit. The inter-assay CV for the folate assay was 8.7% on the basis of repeated measurements of a pooled control.
Statistical analysis. Folate content (means 6 SDs) in wheat rolls under storage conditions were analyzed using 1-way ANOVA with an a of 0.05. We estimated that a sample size of 10 participants/group would allow us to detect a difference in erythrocyte folate of as small as 0.30 mmol/L with a SD of 0.30 mmol/L between either the folate-fortified wheat roll group and the placebo group with an a of 0.05 and 90% power (21) . To account for attrition, we recruited 15 participants/group.
Compliance between treatment groups was compared using ANOVA. The primary outcome measures were erythrocyte and plasma folate concentrations at 16 wk. Data were analyzed as intent-to-treat where, in the case of missing values, the last available value for that participant was carried forward. As-treated analysis was also carried out where dropouts were excluded from the analysis. The differences in erythrocyte and plasma folate concentrations between treatment groups at 16 wk were determined by regression analysis, with adjustment for baseline folate concentrations. A Bonferroni post hoc test was used to adjust for multiple comparisons. Results were considered significant at P < 0.05. All analyses were performed using SPSS Statistics 18.0 for Macintosh. Values in the text are means 6 SDs unless otherwise indicated.
Results
Microencapsulation improved L-5-MTHF stability in the wheat rolls during the baking process ( Table 1) . There were no significant changes in the L-5-MTHF content of the wheat rolls when stored at 4°C up to 7 d. The amount of L-5-MTHF and folic acid in the fortified wheat rolls did not significantly differ.
Participant flow and follow-up are given in Figure 1 . Of the 6 participants who dropped out, 2 cited personal reasons, 2 were going traveling, one was too busy, and one was moving to another city. Among those who completed the study, compliance did not differ between treatment groups (P = 0.84). Overall, 25 participants consumed >90%, 8 consumed 80-90%, and 6 consumed <80% of their wheat rolls. Participant characteristics are given in Table 2 . The age of the participants was 25.6 6 6.3 y, with the majority (70%) <30 y. More than 70% of participants were non-white, with 14 identifying as Chinese, 12 other Asian, and 7 other.
In the intent-to-treat analysis at 16 wk, the erythrocyte and plasma folate concentrations were greater in the L-5-MTHF and folic acid groups compared with the placebo group (P # 0.001) ( Table 3 ). The L-5-MTHF and folic acid groups did not differ in either erythrocyte (P = 0.57) or plasma folate (P = 1.00). Analysis using the as-treated method did not appreciably alter the results.
Discussion
Enriched wheat flour is fortified with folic acid in Canada and the United States and as such, bread is a major vehicle for providing folic acid to the population. If L-5-MTHF is to be used as a fortificant in place of folic acid, it must be stable in baked foods such as bread. Here, we added to our previous work showing that microencapsulated L-5-MTHF is stable in baked products by demonstrating that wheat rolls fortified with microencapsulated L-5-MTHF increase erythrocyte and plasma folate concentrations to a similar extent as wheat rolls fortified with equimolar folic acid. Microencapsulation of L-5-MTHF, therefore, did not adversely affect folate absorption. That free L-5-MTHF added to bread can be absorbed has been previously demonstrated; <10% of the ingested dose of 13 C-labeled L-5-MTHF was recovered in the stoma of ileostomy patients (22) . Unfortunately, bread making in the previous study resulted in a 65% loss of L-5-MTHF compared with only 25% for folic acid (23) . Similarly, when we produced bread from flour fortified with free L-5-MTHF, we experienced a 50% loss compared with only 10% loss of folic acid (19) . Microencapsulation of L-5-MTHF in the present study with sodium ascorbate using a modified starch reduced losses of L-5-MTHF in bread to <10% even after 7 d of storage (17) . The effect of foods fortified with L-5-MTHF on blood folate concentrations has not, to our knowledge, been previously studied. However, a number of investigators have compared the bioavailability of folic acid added to food with a supplement. Early studies, both short term and chronic, indicated that foods made with grains fortified with folic acid were less bioavailable than folic acid when offered as a supplement or added to drinking water (24) (25) (26) . However, these studies may not have accounted for folate losses during food production and preparation. More recent studies, including those using stable isotope methodologies, have shown that folic acid in foods containing enriched grains have similar bioavailability compared with supplements (27) (28) (29) (30) .
We acknowledge a number of study limitations. First, the amount of L-5-MTHF and folic acid added to wheat rolls in our study was considerably higher than that used in most countries where mandatory folic acid exists (i.e., United States, 140 mg/ 100 g of flour). Nevertheless, we would expect that lower doses of L-5-MTHF added to flour would be effective as supplementation with as little as 113 mg/d L-5-MTHF increased erythrocyte and plasma folate (10) . Second, our sample size may have been too small to detect significant differences in the erythrocyte folate concentration between the fortified wheat roll groups. Erythrocyte folate was 0.11 mmol/L higher at 16 wk in the group receiving the L-5-MTHF-fortified wheat rolls than the folic acid wheat rolls. Finally, the study may not have been of sufficient duration to reach a steady state for erythrocyte folate. Sixteen weeks is sufficiently long for plasma folate to reach a steady state in response to a daily fixed dose of folate but not erythrocyte folate (31, 32) .
In conclusion, this study has shown that wheat rolls fortified with microencapsulated L-5-MTHF increased erythrocyte and plasma folate concentrations relative to a placebo bread in a healthy population during 16 wk. Further, the blood folate concentrations achieved with L-5-MTHF did not significantly differ from those achieved with equimolar folic acid-fortified bread. L-5-MTHF is an approved food additive in several countries, including the United States and parts of Europe. Some countries have been reluctant to mandate the fortification of foods due to safety concerns surrounding folic acid (33) . The most often cited concern has been the potential for masking the hematological symptoms of vitamin B-12 deficiency, concerns that would be reduced by replacing folic acid with L-5-MTHF as a fortificant. In addition, L-5-MTHF may have other safety advantages over folic acid, but these remain to be proven. 2 Baseline adjusted means 6 SDs. Means in a column without a common superscript letter differ, P , 0.05. 3 Values are means (95% CIs) adjusted for baseline concentrations relative to placebo. 4 Last value carried forward in the case of missing values. 5 Excludes dropouts.
